Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare disease with an acute and severe clinical presentation. The anti-von Willebrand factor caplacizumab was licensed for adults with aTTP based on prospective controlled trials. However, until now, there was no Brazilian experience with this...

Descripción completa

Detalles Bibliográficos
Autores principales: de Oliveira Boechat, Tiago, de Holanda Farias, João Samuel, Ribeiro, Eduardo Flávio Oliveira, de Andrade, Michaela Larissa Lobo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101538/
https://www.ncbi.nlm.nih.gov/pubmed/37055582
http://dx.doi.org/10.1007/s00277-023-05211-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101538/
https://www.ncbi.nlm.nih.gov/pubmed/37055582
http://dx.doi.org/10.1007/s00277-023-05211-8

Ejemplares similares